• Wajida Mazher Civil Hospital Karachi
  • Jamshed Ali Dow university of Health Sciences
  • Saadia Abubakar Dow University Of Health Sciences
  • Saqib Basar Dow university of Health Sciences
  • Ghulam Murtaza Civil Hospital Karachi


Gaucher’s disease is the most common lysosomal storage disease which occurs due to a deficiency of the enzyme glucocerebrosidase. This enzyme deficiency leads to accumulation of glucocerebrosidase in the cells of macrophage-monocyte system. It is inherited as an autosomal recessive mutation and has three clinical subtypes. The disease presents with anaemia, hepatosplenomegaly, skeletal disorders and organ dysfunction. We present the case of an 18-month old male child who had presented to Civil Hospital, Karachi with fever, progressive pallor, abdominal distention for 6 months and was diagnosed as a case of type 1 Gaucher’s disease on the basis of low leukocyte glucocerebrosidase activity, raised plasma chitotriosidase and the presence of Gaucher cells on bone marrow biopsy. The disease was treated with Intravenous replacement of the enzyme Imiglucerase (cerezyme) and the patient was followed. An informed Consent of the parents was taken prior to the writing of the manuscript.Keywords:  Gaucher Disease; Imiglucerase; Enzyme Replacement therapy


Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program 2012;2012(1):13–8.

Bin Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, et al. Velaglucerase Alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013;88(3):179–84.

Lee JY, Lee BH, Kim GH, Jung CW, Lee J, Choi JH, et al. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr 2012;55(2):48–53.

Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther 2015;9:4639–47

Cheema HA, Malik HS, Parkash A, Fayyaz Z. Spectrum of Inherited Metabolic Disorders in Pakistani Children Presenting at a Tertiary Care Centre. J Coll Physicians Surg Pak 2016;26(6):498–502.

Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother 2013;47(9):1182–93.

Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104(5):1253–7.

Kamath RS, Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 2014;43(10):1353–60.

Zimran A. How I treat Gaucher disease. Blood 2011;118(6):1463–71.

Elstein D, Hughes D, Goker‐Alpan O, Stivel M, Baris HN, Cohen IJ, et al. Outcome of pregnancies in women receiving velaglucerase Alfa for Gaucher disease. J Obstet Gynaecol Res 2014;40(4):968–75.

Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase Alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118(22):5767–73.